Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Levoamlodipine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Blue Water Vaccines
Deal Size : $8.5 million
Deal Type : Acquisition
Details : Blue Water expands its commercial portfolio by purchasing six FDA-approved assets across multiple indications, including cardiology, otic infections, and pain management. The assets also include Conjupri (levamlodipine), a calcium channel blocker for the...
Brand Name : Conjupri
Molecule Type : Small molecule
Upfront Cash : $8.5 million
June 14, 2023
Lead Product(s) : Levoamlodipine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Blue Water Vaccines
Deal Size : $8.5 million
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?
Reset All
